TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Portnoy Law Firm
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors

Skye Bioscience investors can file a class action lawsuit for securities purchased between November 4, 2024 and October 3, 2025. The action follows Skye's October 6, 2025 announcement that its Phase 2a study of nimacimab failed to achieve its primary weight loss endpoint and showed lower than expected drug exposure, causing the stock to plummet 60% to $1.90 per share.

Insights
WMT   neutral

Subsidiary involved in a routine property lease transaction with no major strategic implications


SKYE   negative

The company's lead drug candidate (nimacimab) failed to meet primary endpoints in clinical trials, resulting in a 60% stock price decline. This represents a significant setback for the company's pipeline and investor value, triggering a class action lawsuit.